(51) International Patent Classification 5: C07F 5/00

(11) International Publication Number: WO 91/17168
(43) International Publication Date: 14 November 1991 (14.11.91)

(21) International Application Number: PCT/US91/02988
(22) International Filing Date: 1 May 1991 (01.05.91)
(30) Priority data: 517,219 1 May 1990 (01.05.90) US


(72) Inventor: KUNG, Hank, F.; 525 Foxglove Lane, Wynnewood, PA 19096 (US).


(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published With international search report.

(54) Title: GALLIUM-LABELLED IMAGING AGENTS

(57) Abstract

Complexes prepared from gallium radioisotopes and ligands such as tetraethylcyclohexyl-bis-aminoethanethiol (BAT-TECH) are disclosed which, because of their high uptake in the heart and lipid-solubility, should be useful for myocardial perfusion imaging.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>Code</th>
<th>Country</th>
<th>Code</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>AT</td>
<td>Austria</td>
<td>ES</td>
<td>Spain</td>
</tr>
<tr>
<td>AU</td>
<td>Australia</td>
<td>FI</td>
<td>Finland</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>FR</td>
<td>France</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GA</td>
<td>Gabon</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>GB</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>GN</td>
<td>Guinea</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>GR</td>
<td>Greece</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>IT</td>
<td>Italy</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KP</td>
<td>Democratic People's Republic of Korea</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KR</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LK</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>CS</td>
<td>Czechoslovakia</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>ML</td>
<td>Mali</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>MR</td>
<td>Mauritania</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td>NL</td>
<td>Netherlands</td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td>PL</td>
<td>Poland</td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td>SD</td>
<td>Sudan</td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td>SN</td>
<td>Senegal</td>
<td>SU</td>
<td>Soviet Union</td>
</tr>
<tr>
<td>TD</td>
<td>Chad</td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td>US</td>
<td>United States of America</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
GALLIUM-LABELLED IMAGING AGENTS

Background of the Invention

This invention relates to novel imaging agents for positron emission tomography (PET) and, more specifically, to novel lipid-soluble gallium complexes which should possess utility as myocardial imaging agents.

Positron emission tomography (PET) is a technique whereby a three-dimensional reconstruction of in vivo radionuclide distribution is possible, providing images that map and quantitate tissue activity levels. The demand for new and novel positron-emitting radiopharmaceuticals continues to increase as more institutions acquire instrumentation for PET imaging.

There are two gallium radioisotopes, Ga-67 and Ga-68. Both of these gallium radioisotopes possess nuclear properties that make them attractive for use in nuclear medicine. The first, Ga-67, is cyclotron-produced and is commercially available as gallium chloride and gallium citrate. The second, Ga-68, has the distinction of being one of the few short-lived positron emitting radionuclides available from a parent/daughter generator system. The Ge-68/Ga-68 generator is commercially available and is attractive because of its relatively long parent half-life (287 days) and convenient daughter half-life (68 min.). The generator-based radiopharmaceuticals may provide a useful and effective way of PET imaging without an on-site cyclotron.

Numerous gallium-68 radiopharmaceuticals have been reported, and some are in routine use for human studies.
Unfortunately, development of lipophilic gallium-68 tracers for perfusion imaging of the brain and heart has not been successful. There are tris(salicylaldimine) complexes of gallium that might be used for evaluation of myocardial perfusion. (Green, M.A. and Welch, M.J.: Synthesis and crystallographic characterization of a gallium salicylaldimine complex of radiopharmaceutical interest. J. Am. Chem. Soc. 106:3689, 1984; Green, M.A., Welch, M.J., Mathias, C.J., et al: Gallium-68 1,1,1-tris (5-methoxysalicylaldiminomethyl)ethane: A potential tracer for evaluation of myocardial blood flow. J. Nucl. Med. 26:170-180, 1985; Green, M.A.: Synthesis and biodistribution of a series of lipophilic gallium-67 tris(salicylaldimine) complexes. J. Labeled Compounds Radiopharm 23:1221-1222, 1986). However, these agents proved to be unsuitable for clinical use as myocardial perfusion imaging agents because they behave neither as freely diffusible tracers nor as microsphere analogs. Neutral and highly lipid soluble Ga-LICAM complexes have been reported. (Moerlein, S.M., Welch, M.J., Raymond, K.N.: Use of tricate choline legends to alter the biodistribution of gallium-67. J. Nucl. Med. 23:501-506, 1982). These complexes showed little brain uptake, which suggests that lipid-solubility is not the sole requirement for molecules to penetrate the intact blood-brain barrier. No gallium tracers have been developed that effectively cross the barrier for cerebral blood flow studies.

methylthiosemicarbazone). Nucl. Med. Biol., Int. J. Radiat. Appl. Instrum. Part B 14:59-61, 1989). The Cu(PTSM) is based on an \( \text{N}_2\text{S}_2 \) ligand and is a neutral and lipid-soluble compound. After an intravenous injection, the compound passes through the cell membrane, including the intact blood-brain barrier. Apparently, the compound decomposes intracellularly after interacting with sulfurhydryl groups. (Baerga, I.D., Maickel, R.P. and Green, M.A.: Subcellular distribution of tissue radiocopper following intravenous administration of [Cu-62]-Cu(PTSM). J. Nucl. Med. 30:920, 1989 (Abstract No. 812). The regional distribution is a reflection of regional perfusion, a property consistent with "chemical microspheres". Therefore, this agent in combination with the Zn-62/Cu-62 generator may provide a convenient source of radiopharmaceuticals for measuring regional blood perfusion of the brain and heart. However, Ga-68 labeled compounds may offer some advantages because the longer half-lives of the parent and daughter may greatly enhance the clinical potential as PET radiopharmaceuticals.

Recent advances in Tc-99 chemistry of complexes based on \( \text{N}_2\text{S}_2 \) ligands have dramatically enhanced our ability to predict the chemical structure of the final Tc-99m complexes. This series of ligands form strong complexes with (Tc=O)\(^3\). The x-ray crystallography studies of several \( \text{N}_2\text{S}_2 \) complexes have confirmed the (Tc=O)\(^3\) chemical state and the pyramidal core structure.

The use of \( \text{N}_2\text{S}_2 \) ligands to investigate the radiochemistry of indium, a plus three cation, has also been investigated. In particular, a unique indium complex, \([^{113}\text{In}]\text{TE-BAT} \) (tetraethyl-bis-aminoethanethiol) was evaluated, indicating that the complex, when labeled with \(^{111}\text{In} \), may show promise as a possible tracer for myocardial perfusion imaging. (Liu, B-L, Kung, H.F., Jin, Y.T., Zhu, L., and Meng, M.: A new myocardial imaging agent: synthesis, characterization and biodistribution of \([^{113}\text{In}]\text{TE-BAT} \). J. Nucl. Med. 30:367-373, 1989).
Summary of the Invention

It has now been found that stable complexes can be prepared from gallium radioisotopes and the ligand tetraethyl-cyclohexyl-bis-aminoethanethiol (BAT-TECH) or analogs thereof. That such stable complexes could be prepared was highly surprising in view of the fact that gallium ions usually prefer "hard" donor atoms, such as oxygen, rather than nitrogen, and that stable complexes of gallium generally require more than four covalent bonds to the ion. See, for example, Green MA et al., Nucl. Med. Biol., Vol. 16, No. 5, pp. 435-448 (1989).

This invention therefore relates to complexes of the formula:

![Chemical Structure](image)

where

each of $R_1 - R_{14}$ is independently selected from the group consisting of hydrogen, alkyl groups in which one or more carbon atoms is optionally substituted by a heteroatom such as $N$, $O$ or $S$, and phenyl optionally mono- or di-substituted with a substituent selected from the group consisting of $-SR_{15}$, $-OR_{15}$, and $-NR_{15}R_{16}$, where $R_{15}$ and $R_{16}$ are independently selected from $H$ and alkyl groups; or each grouping of $R_1$ and $R_2$, $R_3$ and $R_6$, $R_5$ and $R_9$, $R_7$ and $R_8$, $R_4$ and $R_9$, and $R_{12}$, $R_{13}$ and $R_{14}$ and $R_{15}$ may independently be taken together to form a cyclic alkyl in which one or more carbon atoms is optionally substituted by a heteroatom. Also included within the scope of this invention are pharmaceutically acceptable salts of the complexes of Formula I, such as chloride or bromide salts.

Tests indicate that complexes of Formula I are lipid-
soluble, and that the compounds exhibit high uptake in the heart as well as in the liver. The complexes should therefore be useful as tracers for myocardial perfusion imaging. Since they may be prepared using Ga-68 isotopes, the complexes of the invention also offer the advantage of being available to institutions not having the use of an on-site cyclotron.

**Detailed Description of the Invention**

The ligands which are used in preparing the gallium complexes of this invention may be prepared by methods known in the art, e.g., by the method disclosed, or by methods analogous to that disclosed, by Kung HF, Molnar M, Billings J, Wicks R, Blau M. "Synthesis and Biodistribution of Neutral Lipid-Soluble Tc-99m Complexes Which Cross the Blood Brain Barrier", J. Nucl. Med. 25:326-332 (1984), the disclosure of which is hereby incorporated by reference.

Each of R₁ - R₁₄ may be selected from H, from alkyl groups, preferably having up to ten carbon atoms, or pairs of R₁ and R₂, etc., may be taken together to form a cycloalkyl group, such as cyclohexyl. Each of R₁ - R₁₄ may also be a phenyl group, optionally substituted with one or two groups selected from the group consisting of -SR₁₅, -OR₁₅, and -NR₁₅R₁₆, where R₁₅ and R₁₆ are independently selected from H and alkyl groups, generally alkyl groups having up to ten carbon atoms.

For reasons of ease of synthesis, it is preferred that, in the ligands from which the complexes of Formula I are prepared, R₁ = R₂; R₃ = R₄; R₅ = R₆; R₇ = R₈; R₉ = R₁₀ and R₁₁ = R₁₂ and R₁₃ = R₁₄ or each grouping of R₁ and R₂, R₃ and R₄, R₅ and R₆, R₇ and R₈, R₉ and R₁₀, R₁₁ and R₁₂, and R₁₃ and R₁₄ be taken together to form a ring structure. More preferred complexes of Formula I are those in which, independently, (1) R₃, R₆, R₇, R₈, R₁₀ and R₁₃ are each hydrogen; (2) R₁, R₂, R₃ and R₄ each is an ethyl group; and (3) R₁₁ and R₁₂ are taken together to form a cyclohexyl group. The preferred complex according to this invention is the [Ga(BAT-TECH)]⁺ complex.

Gallium (Ga⁴⁺) reacts with the bisaminoethanethiol
(BAT) ligands and their analogs in millimolar quantities under aqueous conditions. The labelling reaction is pH sensitive, the optimum pH range being within 2.5-5, preferably between 3 and 4. At higher pH, precipitation of the ligand, due to the limited solubility in water, is observed. This pH can be easily maintained by the addition of buffer solution and is therefore easily adaptable for a simple, one step reaction. Both the reaction temperature and the concentration of the ligand in the reaction mixture affect the labeling yield. Best yields are obtained utilizing a reaction temperature above about 40°C and a ligand concentration above about 3 mg/ML.

Tests indicate that the complex formation between Ga⁴⁺ and BAT-TECH ligand is very rapid, simple and occurs in high yield (≥ 95%). The gallium ion and the BAT-TECH appear to form a 1:1 complex with release of two hydrogen ions and the net charge of the no-carrier-added [⁶⁷Ga]BAT-TECH is probably +1. The high labeling efficiency and excellent purity of this labeling reaction requires no further purification before animal study.

The [⁶⁷Ga]BAT-TECH displays fast myocardial uptake and rapid blood and lung washout in rats. The biological behavior of the complex suggests that this agent, as well as related complexes within the scope of Formula I herein and those labeled alternatively with ⁶⁸Ga, should be useful for myocardial perfusion imaging.

Due to the high yield and rapid formation of the complexes of this invention, they should lend themselves easily to formation from materials which could be provided to users in kits. Kits for forming imaging agents would contain, for example, a vial containing a physiologically suitable solution of the appropriate ligand in a concentration and at a pH suitable for optimal complexing conditions. The user would add to the vial an appropriate quantity of gallium radioisotope, preferably ⁶⁸Ga, and subject the resulting reaction mixture to temperatures to promote the complexing reaction. The resulting solution of gallium complex could be
used directly in the patient for PET imaging.

Example 1 - Preparation of 2,9-Dimethyl-2,9-Dimercapto-5-(2-hydroxyphenyl)-4,7-Diazadecane


A. Preparation of α-Amino-2-methoxybenzenacetonitrile

To a solution of 50.0 g (1.0 mol) of sodium cyanide, 53.5 g (1.0 mol) of ammonium chloride, and 60 mL of concentrated ammonium hydroxide in 400 mL of water was added 125 g (0.92 mol) of α-anisaldehyde in 400 aromatic C-C); of dry methanol. After the mixture was stirred for 3 h at 23° C, the methanol was removed under reduced pressure, and the residual solution containing the crude product was diluted with 500 mL of water and extracted with methylene chloride (2 x 400 mL), dried over sodium sulfate, and filtered; the solvent was subsequently removed under vacuum to give an orange oil. By means of column chromatography on silica gel using ethyl acetate as the eluent, the α-amino nitrile compound (A) was separated from the starting material and the side products; IR (neat) 2240 (w, -C≡N), 1600, 1500 cm⁻¹ (s, aromatic C=C); NMR (CDCl₃) 1.03 (2 H, s, NH₂), 3.90 (3 H, s, OCH₃), 5.05 (1 H, s, CH), 7.15 (4 H m, ArH). The α-amino nitrile (yellow oil) was unstable as a free base; therefore it was either used immediately for the next reaction or converted to the tartarate salt.

B. Preparation of D-α-amino-2-methoxybenzenacetonitrile d-Hemitartarate

To a solution of crude compound (A) prepared freshly from 62.5 g (0.46 mol) of α-anisaldehyde in 1 L of benzene-methanol (4:1) was added 60 g (0.40 mol) of d-tartaric acid dissolved in 400 mL of methanol. The resultant flocculent precipitate was filtered, washed with benzene-methanol (2:1), suspended in carbon tetrachloride, filtered, and dried to
produce 80 g (0.26 mol, 55.7%) of dense white powder, (B), mp 218° C. A small sample was recrystallized twice from methanol for elemental analysis: mp 218 degrees C (dec.). Anal. (C₁₃N₂O₂, 1/2CH₃OH) C, H, N.

C. Preparation of α-(Acetylamino)-2-methoxybenzeneacetanilide

Compound (B) (28.0 g, 89.7 mmol) was dissolved into 250 mL of aqueous sodium bicarbonate, pH 8.0, was extracted with methylene chloride (2 x 150 mL). The combined methylene chloride solution was dried over sodium sulfate (anhydrous), filtered, and reduced to approximately 50 mL of light yellow solution under vacuum. This solution was slowly added to 14.6 g (142 mol) of acetic anhydride at 0° C and then stirred for 2 hours at room temperature, after which excess volatiles (CH₂Cl₂, HOAc, Ac₂O) were removed under vacuum. The residue was recrystallized 2 times from ethyl acetate-hexane (1:1) to give 10.65 g (48.1 mmol) of white microcrystalline powder (C): mp 139-140°; IR 3450 (m, N-H), 1695 (s, amide), 1600, 1500 (aromatic C=C), 2250 cm⁻¹ (v, C=N); NMR (CDCl₃) 2.00 (3 H, s, O-CH₃), 3.93 (3 H, s, OCH₃), 6.13 (1 H, d, J₁ = 9 Hz, CH), 7.10 (5 H, m, ArH + NH), Anal. (C₁₃H₁₂N₂O₂) C, H, N, O.

D. Preparation of α-Amino-2-methoxybenzene-ethanamine

To a cold (0° C) solution of 34.0 g (0.90 mol) of LiAlH₄ in 300 mL of dry THF under N₂ was added dropwise crude dry compound (C) dissolved in 200 mL of dry THF, freshly prepared from 125 g (0.92 mol) of o-anisaldehyde. After the mixture was stirred 12 h at room temperature, the excess hydride was decomposed with 1 L of wet THF-ether. The alumina was filtered off, and the organic solvents were evaporated under vacuum to produce approximately 200 mL of an orange oil. The crude product was azeotropically dried with benzene and then fractionally distilled under vacuum (0.5-0.25 torr). The clear oil (distilled at 96-125° C), which represented the majority of the distillate, was found to be primarily 2-(aminomethyl)anisole. The minor fraction (distilled at 124-140° C), (D), approximately 15 mL, was used without further
purification. IR (disappearance) 2250 cm⁻¹, NMR (CDCl₃) 1.57 (4 H s, NH₂), 2.93 (2 H, m, NCH₂), 3.77 (3 H, s, ArOCH₃), 4.12 (1 H, t, J₁ = 6 Hz, NCH), 7.05 (4 H, m, ArH). Anal. (C₁₃H₁₈N₂O) C, H, N, O.

E. Preparation of α-(Acetylamino)-2-methoxybenzeneethanacetamide

To a cold (0°C) solution of 1.0 g (9.8 mmol) of acetic anhydride in 50 mL of ethyl acetate was slowly added approximately 1 mL (5 mmol) of enriched distillate of compound (D). After the mixture was stirred for 2 h at room temperature, the volatile organics were removed under vacuum to leave a white solid. The residue was recrystallized from ethanol-ethyl acetate to yield 1.0 g (66%) of white crystals, (E); mp 199°C; IR (KBr) 3310 (s, N-H), 1640 cm⁻¹ (2, C=), amide 1 band); NMR (CDCl₃) 1.97 (6 H d, J₁ = 3 Hz, NAc), 3.47 (2 H m, NCH₂), 3.85 (3 H, s, ArOCH₃), 5.27 (1 H, m, NCH), 6.20 (1 H, m, NH), 7.03 (5 H, m, ArH + NH). Anal. (C₁₃H₁₈N₂O₂), C, H, N, O.

F. Preparation of 3,3,10,10-Tetramethyl-1,2-dithia-7-(2-methoxyphenyl)-5,8-diazacyclodeca-4,8-diene

To a solution of 6.01 g (29.6 mmol) of 2,2'-dithiobis(2-methylpropanal) in 25 mL of absolute ethanol was added 5.0 g (30.0 mmol) of distilled compound (E). The solution was stirred at 50°C for 30 min and subsequently allowed to stand for 12 h at 4°C, after which a precipitate formed. The precipitate was washed with cold methanol and dried to yield 6.52 g (19.4 mmol, 65.5%) of white powder (F). An analytical sample was recrystallized once from ethyl acetate; mp 121°C; IR (KBr) 1650 (s, C=N), 1600, 1495 cm⁻¹, (w, Ar); NMR (CDCl₃) 1.43 (12 H, d, J = 10 Hz, C(CH₃)₂), 2.90 (1 H, t, J₁ = 9 Hz, NCH), 3.83 (3 H, s, OCH₃), 4.58 (2 H, m, NCH₂), 7.00 (5 H, m, ArH + N=CH), 7.77 (1H, m, ArH). Anal. (C₁₇H₁₈N₂O₂S₂) C, H, N.
G. Preparation of 2,9-Dimethyl-2,9-dimercapto-5-(2-methoxyphenyl)-4,7-diazadecane Hydrochloride

To a solution of 45 mL (153 mmol) of Red-Al (Aldrich Chemical Co.) in 200 mL of dry benzene under N₂ was added dropwise 7.0 g (20.8 mmol) of compound (F) dissolved in 10 mL of dry benzene. After refluxing for 1 h, the solution was chilled to 0°C and excess hydride decomposed by the slow addition of 50 mL of concentrated HCl. The pH was adjusted to 10 with concentrated aqueous NaOH. The solids were removed via filtration and the benzene evaporated under vacuum to produce a foul-smelling purple oil. The oil was dissolved into 60 mL of absolute ethanol at 0°C, and compound was caused to precipitate by bubbling dry HCl gas. The precipitate was filtered, rinsed with ethanol, and dried to produce 5.95 g (68.8%) of white powder (G). An analytical sample was prepared by recrystallization once from ethanol: mp 182-188°C; IR (neat) 3300 (w, NH str); 2550 cm⁻¹ (w, SH str); NMR (CDCl₃) (free base) 1.37 (12 H, s, C(CH₃)₂), 2.00 (4 H, s, SH, NII), 2.65 (6 H, m, NCH₂), 3.82 (3 H, s, ArOCH₃), 4.13 (1 H, m, NCH), 7.13 (4 H, m, ArH). Anal. (C₁₇H₁₇N₂O₂S₂) C, H, N, S.

H. Preparation of 2,9-Dimethyl-2,9-mercaptop-5-(2-hydroxyphenyl)-4,7-diazadecane

To a suspension of compound (G), 5.95 g (14.3 mmol) in 60 mL of absolute ethanol was added a solution of 0.6 g (26.8 mmol) of sodium in 20 mL of absolute ethanol. After the mixture was stirred for 30 minutes, the sodium chloride was filtered off and the solvent removed under vacuum to produce the free-base form of compound (G) as a clear oil in quantitative yield. The oil (4.89 g, 14.3 mmol) was dissolved into 50 mL of CH₂Cl₂ at 0°C and added dropwise to boron tribromide (72 mmol in 72 mL of CH₂Cl₂) at 0°C under N₂. After addition, the solution was refluxed for 12 h, then allowed to cool to room temperature, and treated with 200 mL of water. The aqueous phase was adjusted to pH 8 with NaHCO₃, and the methylene chloride layer was separated, dried over Na₂SO₄, and filtered; the solvent was evaporated under vacuum to produce
a crimson oil (5.3 g) that solidified upon standing for 12 hours at room temperature. The crude solid was washed with hexane 2-propanol (2 x 5 ml) and multiple recrystallizations yielded a foul-smelling white powder; yield 0.484 g (10.3%); mp 85°C; IR (CCl₄) 3370 (2, NH str), 1600 cm⁻¹ (m, Ar str); NMR (CDCl₃) 1.40 (14 H, s, C(CH₃)₂ + NH), 2.67 (4 H, d, J₁ = 1.5 Hz, NCH₂), 2.93 (2 H, d, J₁ = 3 Hz, NCH₂), 3.72 (1 H, t, J₁ = 8 Hz, NCH), 7.00 (4 H m, ArH). Anal. (C₁₅H₂₈N₂OS₂) C, H, N, S.

Example 2. Preparation of Tetraethyl-bis-aminoethanethiol (BAT-TECH)

BAT-TECH was prepared by a method analogous to that disclosed in Example 1, using cyclohexanone in place of o-anisaldehyde as a starting material in Step A. One other difference is that lithium aluminum hydride was employed for the last reduction step of diimine intermediate. The dimercapto hydrochloride salt of BAT-TECH was precipitated and used for this study. Ga-67 was obtained from Mallinckrodt as gallium citrate. Gallium-68 was obtained by eluting a Ge-68/Ga-68 generator with 0.1 N HCl.

Example 3. Radiolabeling

No-carrier-added [⁶⁷Ga] citrate (1 mCi/mL) was added to a test tube containing the BAT-TECH ligand (1 mg) in 0.5 mL of water and adjusting the pH to 3.1 by the dropwise addition of a solution of 5% NaOH. The mixture was vortexed and kept in a heating block at 75°C for 0.5 hour. The percent labeling yield was measured by thin-layer chromatography (Silica gel plate, developing solvent: acetone:acetic acid 3:1, V/V, Rₐ=0.1 and 0.7 for Ga-citrate and Ga-BAT-TECH, respectively). The radiochemical purity usually is over 96%. This material was used directly for animal studies. Effect of acidity and the reaction time on the formation of this complex was determined by the same TLC technique.

For a monkey imaging study, Ga-68 was eluted from a ⁶⁶Ge/⁶⁸Ga generator and extracted in a 6 N HCl solution with ether (3 x 1.5 mL). The combined extract was dried under a stream of nitrogen. To this residue, BAT-TECH ligand (3
mg/mL, pH3.1) was added. The mixture was heated in a heating block at 75°C for 15 min. After filtration through a 0.22 micron filter, the material was assayed and injected into a monkey. The whole preparation was accomplished in 40 min.

Conductivity data, elemental analysis data, infrared, proton NMR spectroscopy and mass spectral measurements were consistent with the formulation [Fa(BAT-TECH)Cl]. Examination of the IR and NMR data suggest that, as with the Tc=O analogs of the BAT ligands, complexation occurs by gallium binding to the two sulfur atoms and the two nitrogen atoms. The IR data of the complex show no band attributable to the SH stretching frequency, which appears as a strong band at 2420 cm⁻¹ in the spectrum of the ligand. The proton NMR data (27°C, CDCl₃) show resonances for all of the diastereotopic methylene portons adjacent to the nitrogen atoms of the ligand backbone. The observation of well resolved resonances of the individual methylene protons, similar to that observed for proton NMR of the Tc=O complexes of N₂S₂ ligands, suggests that the gallium binds to the nitrogen atoms and may impose a rigid structure on an otherwise flexible ligand. Conductivity measurements (0.42 ohm⁻¹cm⁻³mol⁻¹; 10⁻³ M, acetonitrile) indicate that the molecule is neutral in this solvent. The mass spectral data (chemical ionization) show a molecular ion cluster at m/z=465 with an isotope distribution pattern in agreement with [M+H]⁺ (where M=[Ga(BAT-TECH)Cl]) and fragmentation from this molecular ion to give [M-Cl]⁺, M/z=430, indicating the cleavage of the chloride ion.

At tracer concentrations, the aqueous chemistry has been studied using [⁶⁷Ga] gallium citrate as the starting material. The net charge in an aqueous solution was found to be +1. The ratio of ligand to ⁶⁷Ga was determined to be a:a. Presumably, under the conditions required for the preparation of the ⁶⁷Ga complex, the cationic [⁶⁷Ga(BAT-TECH)]⁺ species is formed. Using reverse phase HPLC (PRP-1 column, mobile phase=90/10 CH₃CN/5mM DMGA, ph-7; flow rate 1mL/min), [⁶⁷Ga₉BAT-TECH]⁺ elutes at 6.5 min., suggesting that the complex is very lipid-soluble.
The partition coefficient of the $[^{67}\text{Ga}](\text{BAT-TECH})^+$ complex was measured by mixing the compound with 3 g each of 1-octanol and buffer (pH 7.0 or 7.4, 0.1 M phosphate) in a test tube. This test tube was vortexed for 3 minutes at room temperature and then centrifuged for 5 minutes. Two weighed samples (0.5 g each) from the 1-octanol and buffer layers were counted in a well counter. The partition coefficient was determined by calculating the ratio of counts per minute/gram of octanol to that of buffer. Samples from the octanol layer were repartitioned until consistent partition coefficient values were obtained. The measurement was repeated three times. The partition coefficient of the complex was determined to be $147 \pm 5.18$ (pH 7.0) and $72.3 \pm 3.47$ (pH 7.4).

4. Biodistribution in Rats

Biodistribution of $[^{67}\text{Ga}](\text{BAT-TECH})$ was studied in male Sprague Dawley rats (200-250 g) which were allowed access to food and water ad lib. Saline solution containing $[^{67}\text{Ga}](\text{BAT-TECH})$ in a volume of 0.2 ml was injected directly into a femoral vein. Rats were sacrificed (at various time points, 2, 30 and 60 min., post injection) by cardiac excision under ether anesthesia. The organs of interest were removed and counted using a well gamma counter. Percent dose per organ was calculated by comparison of tissue counts to suitably diluted aliquots of injected material. Total activities of blood and muscle were calculated assuming that they are 7% and 40% of total body weight, respectively. Each time point consists of a group of three rats.

As shown in Table 1, after an iv injection of $[^{67}\text{Ga}](\text{BAT-TECH})$ in rats, a significant heart uptake (1.68% dose/organ) at 2 min was observed. The heart uptake dropped to 0.52% dose/g at 30 min and 0.26% dose/g at 1 hour. The heart uptake values are better than those reported for $[^{68}\text{Ga}](5\text{-MeOSal}),\text{TAME}$ (0.97, 0.23 and 0.14% dose/whole heart in rats at 1, 30 and 60 min postinjection, respectively). The heart to lung and heart to blood ratios for this complex are also comparable to or superior to those reported for $[^{68}\text{Ga}](5-$
MeOSal), TAME. There is significant uptake in the liver which does not wash out with time.
Table 1
Biodistribution of [\(^{67}\text{Ga}\)]BAM-TECH in rats after an iv injection
(% dose/organ)

<table>
<thead>
<tr>
<th>Organ</th>
<th>2 min</th>
<th>30 min</th>
<th>60 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>10.18±0.30</td>
<td>3.58±0.08</td>
<td>4.54±1.10</td>
</tr>
<tr>
<td>Heart</td>
<td>1.68±0.12</td>
<td>0.52±0.08</td>
<td>0.26±0.02</td>
</tr>
<tr>
<td>Muscle</td>
<td>13.89±3.21</td>
<td>21.14±2.18</td>
<td>10.79±1.85</td>
</tr>
<tr>
<td>Lung</td>
<td>2.07±0.07</td>
<td>0.46±0.09</td>
<td>0.37±0.009</td>
</tr>
<tr>
<td>Kidney</td>
<td>6.94±0.31</td>
<td>2.00±0.10</td>
<td>1.06±0.14</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.50±0.06</td>
<td>0.15±0.009</td>
<td>0.11±0.001</td>
</tr>
<tr>
<td>Liver</td>
<td>21.52±1.11</td>
<td>33.54±4.42</td>
<td>46.41±2.39</td>
</tr>
<tr>
<td>Skin</td>
<td>5.44±1.65</td>
<td>7.56±1.60</td>
<td>5.78±0.92</td>
</tr>
<tr>
<td>Brain</td>
<td>0.02±0.004</td>
<td>0.01±0.001</td>
<td>0.01±0.002</td>
</tr>
</tbody>
</table>

2,9-Dimethyl-2,9-mercapto-5-(2-hydroxyphenyl)-4,7-diazadecane was labelled, and the biodistribution of the labelled compound measured, by analogous methods. The results are presented in Table 2.

Table 2
Biodistribution of [\(^{67}\text{Ga}\)]2,9-Dimethyl-2,9-Dimercapto-5-(2-hydroxyphenyl)-4,7-diazadecane in rats after an iv injection
(% dose/organ)

<table>
<thead>
<tr>
<th>Organ</th>
<th>2 min</th>
<th>30 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>11.24±.724</td>
<td>2.823±.182</td>
</tr>
<tr>
<td>Heart</td>
<td>.94±.094</td>
<td>.380±.039</td>
</tr>
<tr>
<td>Muscle</td>
<td>14.39±2.91</td>
<td>17.49±1.37</td>
</tr>
<tr>
<td>Lung</td>
<td>1.236±.155</td>
<td>.69±.481</td>
</tr>
<tr>
<td>Kidney</td>
<td>5.677±.266</td>
<td>1.204±.080</td>
</tr>
<tr>
<td>Spleen</td>
<td>.43±.085</td>
<td>.155±.022</td>
</tr>
<tr>
<td>Liver</td>
<td>20.93±4.13</td>
<td>25.31±1.09</td>
</tr>
<tr>
<td>Skin</td>
<td>.137±.023</td>
<td>.079±.004</td>
</tr>
<tr>
<td>Brain</td>
<td>.026±.002</td>
<td>.019±.001</td>
</tr>
<tr>
<td>Brain/Blood</td>
<td>.028</td>
<td>.073</td>
</tr>
</tbody>
</table>
Example 5. Imaging Study in a Monkey

A monkey (10 lb) was sedated with ketamine (50 mg i.m.) and then anesthetized with nembutal (0.2 mL, 25 mg/mL, additional amount was used as needed). The monkey was positioned in the PENN-PET[38] tomograph and the scan started at 7 min after an iv injection of [68Ga]BAT-TECH (424 µCi/3 mL of saline). The monkey was scanned for 15 min and a total of 5.8 million counts were collected. Data were reconstructed in 45 overlapping 8 mm thick slices using filtered backprojection with a Hanning filter. In this preliminary study, no attenuation correction was performed. Slice spacing was 2 mm, yielding image data on a 2x2x2 mm grid suitable for displaying transverse, sagittal, or coronal sections.
WHAT IS CLAIMED IS:

1. Radioisotopic complexes of the formula:

\[
\begin{array}{c}
\text{I} \\
\text{where}
\end{array}
\]

where each of \( R_1 \) – \( R_{14} \) is independently selected from the group consisting of hydrogen, alkyl groups in which one or more carbon atoms is optionally substituted by a heteroatom such as \( N, \ O \) or \( S \), and phenyl optionally mono- or disubstituted with a substituent selected from the group consisting of \(-S\text{R}_{15}\), \(-O\text{R}_{15}\), and \(-\text{N}\text{R}_{15}\text{R}_{16}\), where \( R_{15} \) and \( R_{16} \) are independently selected from \( H \) and alkyl groups; or each grouping of \( R_2 \) and \( R_3 \), \( R_4 \) and \( R_5 \), \( R_6 \), \( R_7 \), \( R_8 \), \( R_{11} \), \( R_{12} \), and \( R_{14} \) may independently be taken together to form a cyclic alkyl in which one or more carbon atoms is optionally substituted by a heteroatom, and pharmaceutically acceptable salts thereof.

2. A complex of Claim 1 in which, independently, \( R_1 = R_2 \) or may be taken together to form a ring structure; \( R_3 = R_4 \) or may be taken together to form a ring structure; \( R_5 = R_6 \) or may be taken together to form a ring structure; \( R_7 = R_8 \) or may be taken together to form a ring structure; \( R_{11} = R_{12} \) or may be taken together to form a ring structure and \( R_{13} = R_{14} \) or may be taken together to form a ring structure.

3. A complex of Claim 1 in which \( R_5 \), \( R_6 \), \( R_7 \), \( R_8 \), \( R_{13} \), and \( R_{14} \) are each hydrogen.

4. A complex of Claim 1 in which each of \( R_1 \), \( R_2 \), \( R_3 \)
and R₄ is an ethyl group.

5. A complex of Claim 1 in which R₁₁ and R₁₂ are taken together to form a ring structure.

6. A complex of Claim 1 in which R₁₁ and R₁₂ are taken together to form a cyclohexyl group.

7. A complex of Claim 1 in which R₃, R₅, R₇, R₈, R₁₃ and R₄ are each hydrogen and in which each of R₂, R₂, R₃ and R₄ is an ethyl group.

8. A complex of Claim 7 in which R₁₁ and R₁₂ are taken together to form a cyclohexyl group.

9. A complex of Claim 1 in which the Ga atom is Ga-68.

10. A complex of Claim 2 in which the Ga atom is Ga-68.

11. A complex of Claim 3 in which the Ga atom is Ga-68.

12. A complex of Claim 4 in which the Ga atom is Ga-68.

13. A complex of Claim 5 in which the Ga atom is Ga-68.

14. A complex of Claim 6 in which the Ga atom is Ga-68.

15. A complex of Claim 7 in which the Ga atom is Ga-68.

16. A complex of Claim 8 in which the Ga atom is
17. A radioisotopic imaging agent comprising a complex of Claim 1.

18. A kit for preparing a radioisotopic imaging agent of Claim 17 comprising a vial containing, in a concentration and at a pH suitable for optimal complexing conditions with radioisotopic gallium ion, a physiologically suitable solution of a ligand of the formula

\[
\begin{align*}
\text{R}_1 & \quad \text{R}_2 \\
\text{R}_3 & \quad \text{R}_4 \\
\text{R}_5 & \quad \text{R}_6 \\
\text{R}_7 & \quad \text{R}_8 \\
\text{R}_9 & \quad \text{R}_{10} \\
\text{R}_{11} & \quad \text{R}_{12} \\
\text{R}_{13} & \quad \text{R}_{14}
\end{align*}
\]

where each of \( R_1 - R_{14} \) is independently selected from the group consisting of hydrogen and alkyl groups in which one or more carbon atoms is optionally substituted by a heteroatom such as \( N, O \) or \( S \), or each grouping of \( R_1 \) and \( R_2 \), \( R_3 \) and \( R_4 \), \( R_5 \) and \( R_6 \), \( R_7 \) and \( R_8 \), \( R_9 \) and \( R_{10} \), \( R_{11} \) and \( R_{12} \), and \( R_{13} \) and \( R_{14} \) may be taken together to form a cyclic alkyl in which one or more carbon atoms is optionally substituted by a heteroatom.
INTERNATIONAL SEARCH REPORT

INTERNATIONAL APPLICATION No. PCT/US91/02988

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *

<table>
<thead>
<tr>
<th>INT. Cl.</th>
<th>07F 5/00</th>
</tr>
</thead>
<tbody>
<tr>
<td>US. Cl.</td>
<td>534/10</td>
</tr>
</tbody>
</table>

II. FIELDS SEARCHED

<table>
<thead>
<tr>
<th>Classification System</th>
<th>Classification Symbols</th>
<th>Minimum Documentation Searched</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>424/1.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>534/10</td>
<td></td>
</tr>
</tbody>
</table>

Documentation searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched."*

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of Document, 11 with indication, where appropriate, of the relevant passages 12</th>
<th>Relevant to Claim No. 13</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US, A, 4,885,363 (TWEEDUE et al) 05 December 1989</td>
<td></td>
</tr>
</tbody>
</table>

* Special categories of cited documents: 18

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search 10 JUNE 1991

Date of Mailing of this International Search Report 09 JUL 1991

International Searching Authority ISA/US

Signature of Authorized Officer

John S. Naples
V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. [ ] Claim numbers ... ... ... because they relate to subject matter not required to be searched by this Authority, namely:

2. [ ] Claim numbers ... ... ... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. [ ] Claim numbers ... ... ... because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

I. Claims 1-17, drawn to a radioisotopic complex, classified in Class 534, subclass 10.
II. Claim 18, drawn to a kit, classified in Class 424, subclass 1.1.

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. [X] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: 1-17

4. [ ] As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

[ ] The additional search fees were accompanied by applicant's protest.
[ ] No protest accompanied the payment of additional search fees.
I. Claims 1-17, drawn to a radioisotopic complex, classified in Class 534, subclass 10.

II. Claim 18, drawn to a kit, classified in Class 424, subclass 1.1.

The above inventions lack unity under PCT Rule 13 since, for example Group II includes a vial which the Group I complex does not contain. In addition, the Group I complex comprises a radionuclide not found in the Group II kit.